title: Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
authors.affiliation: Oncology Analytics, Plantation, Florida, USA.
authors.forename: Kevin
authors.initials: K
authors.lastname: Knopf
authors.affiliation: University College London, London NW11 7ED, UK baum.michael3@gmail.com.
authors.forename: Michael
authors.initials: M
authors.lastname: Baum
authors.affiliation: Oncology Analytics, Plantation, Florida, USA.
authors.forename: William S
authors.initials: WS
authors.lastname: Shimp
authors.affiliation: University of South Carolina College of Pharmacy and Hollings Cancer Center of the Medical University of South Carolina, Columbia and Charleston, South Carolina, USA.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
authors.affiliation: Oncology Analytics, Plantation, Florida, USA.
authors.forename: Dinah
authors.initials: D
authors.lastname: Faith
authors.affiliation: Oncology Analytics, Plantation, Florida, USA.
authors.forename: Marc L
authors.initials: ML
authors.lastname: Fishman
authors.affiliation: Ambulatory Monitoring, Ardsley, New York, USA.
authors.forename: William J M
authors.initials: WJ
authors.lastname: Hrushesky
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D015415:Biomarkers; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D018572:Disease-Free Survival; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers